Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.92) per share which missed the analyst consensus estimate of $(0.74) by 24.32 percent. This is a 17.95 percent decrease over losses of $(0.78) per share from the same period last year.